In a study published in Cancer Immunology Research, researchers at Moffitt Cancer Center, led by Amer A. Beg, show how stimulating dendritic cells through the CD40 and interferon β pathways produces strong T-cell activity against tumors and works in conjunction with immune checkpoint inhibitors to produce even stronger responses.
The cancer research community has a reason to celebrate. For the first time, 70% of people are living at least five years beyond their cancer diagnosis. And, as importantly, cancer death rates have been dropping relentlessly—by more than a third since 1991.
